BRPI1008855B8 - derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende - Google Patents

derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende

Info

Publication number
BRPI1008855B8
BRPI1008855B8 BRPI1008855A BRPI1008855A BRPI1008855B8 BR PI1008855 B8 BRPI1008855 B8 BR PI1008855B8 BR PI1008855 A BRPI1008855 A BR PI1008855A BR PI1008855 A BRPI1008855 A BR PI1008855A BR PI1008855 B8 BRPI1008855 B8 BR PI1008855B8
Authority
BR
Brazil
Prior art keywords
anticancer agents
preparation
indole derivatives
pharmaceutical composition
compounds
Prior art date
Application number
BRPI1008855A
Other languages
English (en)
Inventor
Schoentjes Bruno
Claudie Isabelle Amblard Nathalie
Descamps Sophie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI1008855A2 publication Critical patent/BRPI1008855A2/pt
Publication of BRPI1008855B1 publication Critical patent/BRPI1008855B1/pt
Publication of BRPI1008855B8 publication Critical patent/BRPI1008855B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de indol como agentes anticâncer a presente invenção refere-se a compostos de fórmula (i), seu uso para o tratamento de câncer bem como composições farmacêuticas compreendendo os ditos compostos de fórmula (i).
BRPI1008855A 2009-02-04 2010-02-03 derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende BRPI1008855B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09152089 2009-02-04
EP09152089.0 2009-02-04
PCT/EP2010/051316 WO2010089327A2 (en) 2009-02-04 2010-02-03 Indole derivatives as anticancer agents

Publications (3)

Publication Number Publication Date
BRPI1008855A2 BRPI1008855A2 (pt) 2016-03-15
BRPI1008855B1 BRPI1008855B1 (pt) 2020-05-12
BRPI1008855B8 true BRPI1008855B8 (pt) 2021-05-25

Family

ID=40738626

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008855A BRPI1008855B8 (pt) 2009-02-04 2010-02-03 derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende

Country Status (23)

Country Link
US (1) US8541442B2 (pt)
EP (1) EP2393801B1 (pt)
JP (1) JP5612611B2 (pt)
KR (1) KR101730407B1 (pt)
CN (1) CN102307868B (pt)
AR (1) AR075235A1 (pt)
AU (1) AU2010210178B2 (pt)
BR (1) BRPI1008855B8 (pt)
CA (1) CA2749209C (pt)
CL (1) CL2011001860A1 (pt)
CO (1) CO6341625A2 (pt)
EA (1) EA021883B1 (pt)
ES (1) ES2639752T3 (pt)
IL (1) IL214427A (pt)
MX (1) MX2011008195A (pt)
MY (1) MY152018A (pt)
NO (1) NO20111199A1 (pt)
NZ (1) NZ594186A (pt)
SG (1) SG173495A1 (pt)
TW (1) TWI476189B (pt)
UA (1) UA107455C2 (pt)
WO (1) WO2010089327A2 (pt)
ZA (1) ZA201105695B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
CN113480530A (zh) 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
CN106632303A (zh) * 2017-01-09 2017-05-10 湖南华腾制药有限公司 一种6‑噻唑基吲哚衍生物的制备方法
EP3713937A2 (en) 2017-11-20 2020-09-30 Ariagen, Inc. Indole compounds as aryl hydrocarbon receptor (ahr) modulators
CN108659003B (zh) * 2018-04-14 2021-01-26 上海朝晖药业有限公司 一种治疗口腔溃疡的化合物的制备方法
CA3137027A1 (en) 2019-04-15 2020-10-22 Ariagen, Inc. Chiral indole compounds and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CA2350597A1 (en) 1998-12-02 2000-06-08 Barbara Ann Foster Methods and compositions for restoring conformational stability of a protein of the p53 family
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1379239B1 (en) 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
WO2003040402A2 (en) 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
HUP0402003A3 (en) 2001-11-13 2005-06-28 Dimensional Pharm Inc Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
KR101331786B1 (ko) 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
EP1999126B1 (en) 2006-03-22 2010-06-09 Janssen Pharmaceutica, N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
US20100129933A1 (en) * 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
TW200922557A (en) 2007-08-06 2009-06-01 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
US8288377B2 (en) 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
NO20111199A1 (no) 2011-11-04
US8541442B2 (en) 2013-09-24
KR101730407B1 (ko) 2017-04-26
BRPI1008855A2 (pt) 2016-03-15
JP5612611B2 (ja) 2014-10-22
AU2010210178B2 (en) 2014-06-05
EA021883B1 (ru) 2015-09-30
TWI476189B (zh) 2015-03-11
BRPI1008855B1 (pt) 2020-05-12
CN102307868B (zh) 2016-06-22
JP2012516872A (ja) 2012-07-26
CA2749209A1 (en) 2010-08-12
UA107455C2 (uk) 2015-01-12
ZA201105695B (en) 2014-01-29
CN102307868A (zh) 2012-01-04
AU2010210178A1 (en) 2011-07-28
EA201170997A1 (ru) 2012-01-30
CA2749209C (en) 2017-01-10
IL214427A0 (en) 2011-09-27
WO2010089327A3 (en) 2010-10-21
US20110294846A1 (en) 2011-12-01
AR075235A1 (es) 2011-03-16
ES2639752T3 (es) 2017-10-30
KR20110116195A (ko) 2011-10-25
EP2393801A2 (en) 2011-12-14
CO6341625A2 (es) 2011-11-21
EP2393801B1 (en) 2017-07-12
IL214427A (en) 2016-02-29
MY152018A (en) 2014-08-15
CL2011001860A1 (es) 2012-07-20
MX2011008195A (es) 2011-09-06
TW201038552A (en) 2010-11-01
WO2010089327A2 (en) 2010-08-12
NZ594186A (en) 2012-12-21
SG173495A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
BRPI0910388A2 (pt) agentes terapêutico antivirais.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
CO6351783A2 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
SV2011003855A (es) Heteroarilos sustituidos
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
BRPI1008855B8 (pt) derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UY32426A (es) Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
BR112012009310A2 (pt) composto, e, composição farmacêutica
BRPI1014802B8 (pt) profármacos de triptolida.
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
DOP2010000155A (es) Derivados de pirazol como inhibidores de 5-lo
CL2010001432A1 (es) Compuestos derivados de 2-oxo-alquil-1-piperazin-2-ona, afines por los receptores p75ntr; procedimiento para preparar los compuestos; compuesto intermediario; medicamento y composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos utiles para tratar enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2760 DE 28-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.